

Special Issue

Clinical Utility of Pharmacogenetic Testing

Message from the Guest Editor

Pharmacogenetic testing has been widely promoted to support individualized drug prescription by testing for allelic variants that affect the pharmacokinetics and pharmacodynamics of drugs. Within several therapeutic areas, actionable prescribing guidelines have been developed to facilitate the clinical implementation of these tests. However, a meaningful implementation of pharmacogenetic tests not only requires data that associates gene variants with tolerability and efficacy measures, but also shows that test results can be translated into medical decisions leading to improved clinical outcomes. This Special Issue of the *Journal of Personalized Medicine* focusses on the clinical utility of pharmacogenetics testing in selected therapeutic areas. It includes studies that examine the outcome of pharmacogenetic testing as a point of care approach and highlight challenges associated with its clinical implementation.

Guest Editor

Dr. Gesche Jürgens

Clinical Pharmacology Unit, Zealand University Hospital, Roskilde,
Sygehusvej 10, 4000 Roskilde, Denmark

Deadline for manuscript submissions

closed (25 October 2021)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/81259

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on “omics”-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 25 days after submission; acceptance to publication is undertaken in 5.8 days (median values for papers published in this journal in the second half of 2025).